Navigation Links
KADIAN Efficacy Not Affected by Alcohol Consumption

The results of Phase IV study of KADIAN ? (morphine sulfate extended-release) Capsules have been released by Alpharma Inc. (NYSE: ALO), a leading pharmaceutical company. It reveals that the pharmacokinetics// of the long-acting opioid are not significantly affected by the consumption of alcohol.

Results of this pharmacokinetic study, which Alpharma conducted in response to a request by the U.S. Food and Drug Administration (FDA) to assess whether alcohol interferes with the extended-release mechanism of action in long-acting opioids, were presented yesterday at the 23rd Annual Meeting of the American Academy of Pain Medicine (AAPM) in New Orleans, LA.

"This study demonstrated that the extended-release properties of KADIAN? were maintained even in the presence of a significant quantity of alcohol," says Joseph Stauffer, DO, Vice President, Clinical Research & Medical Affairs, Alpharma Pharmaceuticals Division Inc. "We believe this information is valuable for doctors in their assessment of KADIAN?, and we will continue to educate clinicians and patients about the appropriate use of KADIAN? for moderate-to-severe chronic pain. Like most medications, KADIAN? should not be taken with alcohol."

These results indicate that the concomitant use of tested levels of alcohol with KADIAN? has no significant impact on mean morphine blood levels or the timing of morphine release.

The company has provided these data to the FDA and any future labeling implications will be determined following the completion of its review.

Study Design
In the open-label, single-dose, three-way crossover pharmacokinetic drug interaction study, 32 healthy adult male volunteers, 21 to 40 years of age, were randomized to receive:

KADIAN? 100 mg with ethanol (8 ounces of 40 percent alcohol) while fasting;

KADIAN? 100 mg with ethanol (8 ounces of 40 percent alcohol) while fed;

KADIAN? 100 mg with 8 oun ces of water while fasting;

After the three-way crossover, all subjects then received an immediate-release morphine formulation with 8 ounces of water while fasting, as a reference.

Oral naltrexone hydrochloride was administered 12 hours and 2 hours prior to treatment to counter morphine effects.

There were no serious adverse events reported during the study. Most adverse events were mild to moderate, and one was severe, chest pain. All adverse events resolved before the end of the study.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Efficacy Of Meningitis C Vaccine
2. The Efficacy Of Allergy Shots Questioned
3. The Efficacy Of Newer Stents Questioned
4. The Efficacy Of Hormone Replacement Therapy Studied
5. Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief
6. Efficacy of fish oil supplements in pregnancy.
7. Efficacy of Omega 3 Fatty Acids Needs Wider Perspective
8. Thailand To Test Efficacy Of Stem Cell Technology
9. Efficacy Of Sports-Formulated Jelly Beans In Warding Off Fatigue To Be Studied
10. Indian And Chinese Doctors Join Together To Prove The Efficacy Of Herbal Drugs
11. New Study Shows Efficacy of AROMASIN on Early Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from ... May 30th and 31st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... via ... antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper ... thrilled to partner with Cupron® to provide customers with a game changing chair ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Consulting AB that allows for the marketing and ... market analyses through the MarketResearch.com website. The ... access to complete product descriptions and tables of contents ...
Breaking Medicine Technology: